Mysthera was founded by Forty51 Ventures in Europe’s pharma/biotech hub, Basel, in Switzerland in early 2023. The company is a preclinical stage biotech start-up focused on developing first-in-class, oral therapeutics to treat major unmet needs in autoimmune diseases. Our unique approach has potential to transform patient lives in a number of disease settings including glomerulonephritis, rheumatoid arthritis and inflammatory bowel disease. 

We are first to develop PIM kinase inhibitors as therapeutics for multi-lineage immune cell driven autoimmune diseases. The team are experts in PIM kinase and immunology.  The company has raised $3.5m in seed capital.